1.Gastroduodenal Injury in Patients with Low-Dose Enteric Coated Aspirin Treatment.
Hang Lak LEE ; Dong Soo HAN ; Jin Bae KIM ; Joon Yong PARK ; Joo Hyun SOHN ; Joon Soo HAHM ; You Hern AHN
The Korean Journal of Gastroenterology 2003;42(3):190-194
BACKGROUND/AIMS: Low-dose aspirin therapy is widely used to prevent cardiovascular thrombotic events. However, the safety of low-dose aspirin therapy in the gastrointestinal tract is uncertain. Our aim was to evaluate endoscopic findings in patients taking low-dose aspirin. METHODS: Sixty-two patients who received 100 mg enteric coated aspirin daily more than 30 days were included in this study. Patients' medical records and endoscopic data were reviewed retrospectively. As controls, 70 of age- and gender-matched patients who received an endoscopy without gastrointestinal symptoms were employed. RESULTS: The overall prevalence of gastroduodenal mucosal injury was higher in the aspirin group than in the control group. Erosive gastritis was noted more frequently in the aspirin group than in the control group. However, the prevalence of ulcer was not different between the aspirin group and the control group. CONCLUSIONS: Patients treated with low-dose aspirin therapy are more likely to have endoscopic evidence of mucosal damage. Our study suggests that even a low-dose aspirin therapy can induce a gastroduodenal mucosal injury. In the future, a prospective randomized control study is needed.
Aged
;
Aspirin/administration & dosage/*adverse effects
;
Cardiovascular Diseases/prevention & control
;
Esophagitis/chemically induced
;
Female
;
Gastritis/chemically induced
;
Gastrointestinal Diseases/*chemically induced
;
Humans
;
Male
;
Middle Aged
;
Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
;
Tablets, Enteric-Coated/adverse effects
2.Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females.
Ji Oh MOK ; Chan Hee JUNG ; Chul Hee KIM ; Chang Beom RYU ; Yeo Joo KIM ; Sang Jin KIM ; Hyeong Kyu PARK ; Kyo Il SUH ; Myung Hi YOO ; Dong Won BYUN
The Korean Journal of Internal Medicine 2013;28(6):694-700
BACKGROUND/AIMS: This study was performed to compare the mucosal findings after esophagogastroduodenoscopy in two groups before and after the use of alendronate only and following administration of the enteric-coated alendronate (5 mg) and calcitriol (0.5 microg) combined drug (Maxmarvil, Yuyu Co.). METHODS: The study population consisted of 33 postmenopausal healthy female volunteers, aged 50 to 70 years (mean age, 58 +/- 5) without gastrointestinal symptoms and with normal baseline endoscopic findings. Esophagogastroduodenoscopy was performed at baseline and was repeated 2 weeks later after daily intake of Maxmarvil (n = 17 subjects) or alendronate only (n = 16 subjects). Mucosal injury scores were reported by an endoscopist after 2 weeks of treatment with each medication schedule. RESULTS: Esophageal mucosal injuries developed in two of 16 subjects in the alendronate only group and 0 of 17 in the Maxmarvil group. Gastric mucosal injuries developed in eight subjects in the alendronate group and four subjects in the Maxmarvil group; this difference was statistically significant. CONCLUSIONS: The mucosal damage scores for the alendronate group (total score 24) were significantly higher than those for the Maxmarvil group (total score 9) in the esophagus and stomach. Therefore, this study suggested that enteric-coated Maxmarvil is less harmful to gastrointestinal mucosa than alendronate, and may improve the tolerability of osteoporosis medication in clinical practice.
Administration, Oral
;
Age Factors
;
Aged
;
Alendronate/administration & dosage/*adverse effects
;
Bone Density Conservation Agents/administration & dosage/*adverse effects
;
Calcitriol/administration & dosage/*adverse effects
;
Drug Combinations
;
*Endoscopy, Digestive System
;
Esophagus/*drug effects/pathology
;
Female
;
Gastric Mucosa/*drug effects/pathology
;
Humans
;
Middle Aged
;
*Postmenopause
;
Predictive Value of Tests
;
Republic of Korea
;
Sex Factors
;
Tablets, Enteric-Coated
;
Time Factors
;
Treatment Outcome
;
Vitamins/administration & dosage/*adverse effects
3.Improved Gastrointestinal Symptoms and Quality of Life after Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Receiving Tacrolimus.
Hyeon Seok HWANG ; Bok Jin HYOUNG ; Sol KIM ; Ha Young OH ; Yon Su KIM ; Jung Kyung KIM ; Yeong Hoon KIM ; Yong Lim KIM ; Chan Duck KIM ; Gyu Tae SHIN ; Chul Woo YANG
Journal of Korean Medical Science 2010;25(12):1759-1765
It is reported that a conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) relieves gastrointestinal (GI) symptom burden and improves health-related quality of life (HRQoL). However, it is unclear whether renal transplant recipients using tacrolimus receive the same benefit from the conversion. In this prospective, multi-center, open-label trial, patients were categorized into two groups by their GI symptom screening. Equimolar EC-MPS (n=175) was prescribed for patients with GI burdens; those with no complaints remained on MMF (n=83). Gastrointestinal Symptom Rating Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI) were evaluated at baseline and after one month. Patients and physicians completed Overall Treatment Effect (OTE) at one month. EC-MPS-converted patients had worse GSRS and GIQLI scores at baseline than MMF-continued patients (all P<0.001). Significant improvements in GSRS and GIQLI scores were observed for EC-MPS-converted patients at one month, but MMF-continued patients showed worsened GSRS scores (all P<0.05). OTE scale indicated that EC-MPS patients improved in overall GI symptoms and HRQoL more than MMF patients did (P<0.001). In tacrolimus-treated renal transplant recipients with GI burdens, a conversion from MMF to EC-MPS improves GI-related symptoms and HRQoL.
Adolescent
;
Adult
;
Aged
;
Female
;
Gastrointestinal Diseases/*chemically induced
;
Graft Rejection/drug therapy
;
Humans
;
Immunosuppressive Agents/administration & dosage/*adverse effects/therapeutic use
;
Kidney Failure, Chronic/therapy
;
*Kidney Transplantation
;
Male
;
Middle Aged
;
Mycophenolic Acid/administration & dosage/*adverse effects/*analogs & derivatives/therapeutic use
;
Quality of Life
;
Questionnaires
;
Tablets, Enteric-Coated
;
Tacrolimus/therapeutic use